Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P42765

UPID:
THIM_HUMAN

ALTERNATIVE NAMES:
Acetyl-CoA acetyltransferase; Acetyl-CoA acyltransferase; Acyl-CoA hydrolase, mitochondrial; Beta-ketothiolase; Mitochondrial 3-oxoacyl-CoA thiolase; T1

ALTERNATIVE UPACC:
P42765; Q9BUT6

BACKGROUND:
The enzyme 3-ketoacyl-CoA thiolase, located in mitochondria, is pivotal for the aerobic breakdown of fatty acids, facilitating the production of acetyl-CoA. It exhibits a broad range of activities, including the thiolytic cleavage of 3-oxoacyl-CoAs and the synthesis of ketone bodies, indicating its critical role in cellular energy homeostasis and metabolic flexibility.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of 3-ketoacyl-CoA thiolase, mitochondrial is essential for identifying novel therapeutic approaches. Its capacity to regulate beta-oxidation and ketone body production makes it a promising candidate for the treatment of metabolic diseases and enhancing our understanding of energy metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.